Last reviewed · How we verify
CARBIDOPA AND LEVODOPA (CARBIDOPA,LEVODOPA)
CARBIDOPA AND LEVODOPA (generic name: CARBIDOPA,LEVODOPA) is a Aromatic Amino Acid [EPC] drug developed by BIOCON PHARMA LIMITED. It is currently FDA-approved.
Carbidopa and levodopa are used to treat Parkinson Disease and Idiopathic Parkinson's Disease, as well as Depressive Disorder and Depression, according to ClinicalTrials.gov. As a small molecule inhibitor, carbidopa works by inhibiting the enzyme aromatic-L-amino-acid decarboxylase, specifically blocking the conversion of levodopa to dopamine, as per ChEMBL.
At a glance
| Generic name | CARBIDOPA,LEVODOPA |
|---|---|
| Sponsor | BIOCON PHARMA LIMITED |
| Drug class | Aromatic Amino Acid [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Dyskinesia
- Nausea
- Hallucinations
- Confusion
- Dizziness
- Depression
- Urinary tract infection
- Headache
- Dream abnormalities
- Dystonia
- Vomiting
- Upper respiratory infection
Serious adverse events
- Myocardial infarction
- Psychotic episodes including delusions and paranoid ideation
- Seizures including convulsions
- Syncope
- Angioedema
- Gastrointestinal bleeding
- Agranulocytosis
- Hemolytic anemia
- Henoch-Schönlein purpura
- Depression with suicidal tendencies
Key clinical trials
- Single-Center, Open, Randomized, Single-Dose, Completely Repeated Crossover Bioequivalence Study to Evaluate the Effects of the Test/Reference Preparation, Entacapone,Levodopa and Carbidopa Tablets (I (Phase 1)
- Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE) (Phase 1)
- Screening Medications for Cocaine Cessation and Relapse Prevention (Phase 2)
- Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation (Phase 4)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-104: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre Firs (Phase 1)
- A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patient (Phase 2)
- Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects (Phase 3)
- Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, F (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CARBIDOPA AND LEVODOPA CI brief — competitive landscape report
- CARBIDOPA AND LEVODOPA updates RSS · CI watch RSS
- BIOCON PHARMA LIMITED portfolio CI
Frequently asked questions about CARBIDOPA AND LEVODOPA
What is CARBIDOPA AND LEVODOPA?
Who makes CARBIDOPA AND LEVODOPA?
What is the generic name of CARBIDOPA AND LEVODOPA?
What drug class is CARBIDOPA AND LEVODOPA in?
What development phase is CARBIDOPA AND LEVODOPA in?
What are the side effects of CARBIDOPA AND LEVODOPA?
Related
- Drug class: All Aromatic Amino Acid [EPC] drugs
- Manufacturer: BIOCON PHARMA LIMITED — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing